These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 23666610)
1. A microfluidic anti-Factor Xa assay device for point of care monitoring of anticoagulation therapy. Harris LF; Rainey P; Castro-López V; O'Donnell JS; Killard AJ Analyst; 2013 Sep; 138(17):4769-76. PubMed ID: 23666610 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays. Harris LF; O'Brien A; Castro-López V; O'Donnell JS; Killard AJ Thromb Res; 2011 Dec; 128(6):e166-70. PubMed ID: 21872908 [TBL] [Abstract][Full Text] [Related]
3. Comparison of a fluorogenic anti-FXa assay with a central laboratory chromogenic anti-FXa assay for measuring LMWH activity in patient plasmas. Harris LF; Castro-López V; Jenkins PV; O'Donnell JS; Killard AJ Thromb Res; 2011 Dec; 128(6):e125-9. PubMed ID: 21824646 [TBL] [Abstract][Full Text] [Related]
4. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate? Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. Saw J; Kereiakes DJ; Mahaffey KW; Applegate RJ; Braden GA; Brent BN; Brodie BR; Groce JB; Levine GN; Leya F; Moliterno DJ Thromb Res; 2003; 112(5-6):301-6. PubMed ID: 15041274 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma. Brooks MB Vet Clin Pathol; 2004; 33(4):208-14. PubMed ID: 15570557 [TBL] [Abstract][Full Text] [Related]
7. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass. Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414 [TBL] [Abstract][Full Text] [Related]
8. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin. Spinler SA; Wittkowsky AK; Nutescu EA; Smythe MA Ann Pharmacother; 2005; 39(7-8):1275-85. PubMed ID: 15956240 [TBL] [Abstract][Full Text] [Related]
9. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin. Ip BK; Thomson AR; Moriarty HT Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938 [TBL] [Abstract][Full Text] [Related]
10. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333 [TBL] [Abstract][Full Text] [Related]
11. Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins. Harris LF; Castro-López V; Hammadi N; O'Donnell JS; Killard AJ Talanta; 2010 Jun; 81(4-5):1725-30. PubMed ID: 20441964 [TBL] [Abstract][Full Text] [Related]
12. Monitoring of unfractionated heparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent (PiCT®). Schaden E; Jilch S; Hacker S; Schober A; Kozek-Langenecker S Clin Chim Acta; 2012 Dec; 414():202-5. PubMed ID: 23041210 [TBL] [Abstract][Full Text] [Related]
13. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous factor Xa and IIa formation and on thrombelastometry profiles. Cvirn G; Wagner T; Juergens G; Koestenberger M Blood Coagul Fibrinolysis; 2009 Jan; 20(1):71-7. PubMed ID: 20339323 [TBL] [Abstract][Full Text] [Related]
14. Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs. Castro-López V; Harris LF; O'Donnell JS; Killard AJ Anal Bioanal Chem; 2011 Jan; 399(2):691-700. PubMed ID: 20972772 [TBL] [Abstract][Full Text] [Related]
15. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring. Vandiver JW; Vondracek TG Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756 [TBL] [Abstract][Full Text] [Related]
16. Quantification of unfractionated heparin in human plasma and whole blood by means of novel fluorogenic anti-FXa assays. Castro-López V; Harris LF; O'Donnell JS; Killard AJ J Pharm Biomed Anal; 2011 Dec; 56(5):992-7. PubMed ID: 21852056 [TBL] [Abstract][Full Text] [Related]
17. A quick anti-Xa-activity-based whole blood coagulation assay for monitoring unfractionated heparin during cardiopulmonary bypass: a pilot investigation. Hansen R; Koster A; Kukucka M; Mertzlufft F; Kuppe H Anesth Analg; 2000 Sep; 91(3):533-8. PubMed ID: 10960371 [TBL] [Abstract][Full Text] [Related]
18. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506 [TBL] [Abstract][Full Text] [Related]
19. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory. Marmur JD; Lakhani M; El Rouby S; Cavusoglu E J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674 [TBL] [Abstract][Full Text] [Related]
20. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance. Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]